Cytokinetics, Inc.

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

2024 got off to a good start for Vertex with positive Phase III studies of its novel pain therapy, suzetrigine (then known as VX-548), reported in January. The non-opioid, oral selective inhibitor of

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli